Sodium intake, RAAS-blockade and progressive renal disease

Pharmacological Research

Volumn 107, Issue , 2016, Pages 344-351

  De Borst, Martin H ^a   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiotensin converting enzyme blockade; Angiotensin receptor blockade; Chronic kidney disease; Renin angiotensin aldosterone system; Salt; Sodium

Indexed keywords

AMLODIPINE; IRBESARTAN; PLACEBO; SALT INTAKE;

ARTICLE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE FREE SURVIVAL; DRUG EFFECT; END STAGE RENAL DISEASE; FOLLOW UP; HUMAN; MOLECULAR DYNAMICS; POPULATION RESEARCH; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SODIUM EXCRETION; SODIUM INTAKE; ANIMAL; CHRONIC KIDNEY FAILURE; DIET THERAPY; DRUG EFFECTS; HEART; KIDNEY; SALT INTAKE; SODIUM RESTRICTION;

ANIMALS; DIET, SODIUM-RESTRICTED; HEART; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE, DIETARY;

EID: 84962791911     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.03.037     Document Type: Review

References (81)

1. V. Jha, G. Garcia-Garcia, K. Iseki, Z. Li, S. Naicker, B. Plattner, and et al. Chronic kidney disease: global dimension and perspectives Lancet 382 2013 260 272
2. GBD 2013 Mortality, and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 385 2015 117 171
3. P. Rossing, E. Hommel, U.M. Smidt, and H.H. Parving Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients Diabetes 42 1993 715 719
4. J.C. Peterson, S. Adler, J.M. Burkart, T. Greene, L.A. Hebert, L.G. Hunsicker, and et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study Ann. Intern. Med. 123 1995 754 762
5. P. Ruggenenti, A. Perna, L. Mosconi, R. Pisoni, and G. Remuzzi Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) Kidney Int. 53 1998 1209 1216
6. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm, and et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 2003 2154 2169
7. Chronic Kidney Disease Prognosis Consortium, and et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 2010 2073 2081
8. G. Maschio, D. Alberti, G. Janin, F. Locatelli, J.F. Mann, M. Motolese, and et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-converting-enzyme Inhibition in Progressive Renal Insufficiency Study Group N. Engl. J. Med. 334 1996 939 945
9. The GISEN group (Gruppo italiano di studi epidemiologici in nefrologia) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy Lancet 349 1997 1857 1863
10. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N. Engl. J. Med. 342 2000 145 153
11. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, and et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N. Engl. J. Med. 345 2001 861 869
12. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, and et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N. Engl. J. Med. 345 2001 851 860
13. P. Ruggenenti, A. Perna, G. Remuzzi, and G.I.S.E.N. Group Investigators Retarding progression of chronic renal disease: the neglected issue of residual proteinuria Kidney Int. 63 2003 2254 2261
14. F.A. Holtkamp, D. de Zeeuw, P.A. de Graeff, G.D. Laverman, T. Berl, G. Remuzzi, and et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials Eur. Heart J. 32 2011 1493 1499
15. H.J. Lambers Heerspink, M.H. de Borst, S.J. Bakker, and G.J. Navis Improving the efficacy of RAAS blockade in patients with chronic kidney disease Nat. Rev. Nephrol. 9 2013 112 121
16. E. Morales, V.G. Millet, J. Rojas-Rivera, A. Huerta, E. Gutierrez, E. Gutierrez-Solis, and et al. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases Nephrol. Dial Transplant. 28 2013 405 412
17. G.L. Bakris, R. Agarwal, J.C. Chan, M.E. Cooper, R.T. Gansevoort, H. Haller, and et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial JAMA 314 2015 884 894
18. J.K. Humalda, D.J. Goldsmith, R. Thadhani, and M.H. de Borst Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes Nephrol. Dial. Transplant. 30 2015 1988 1994
19. M.H. de Borst, R. Hajhosseiny, H. Tamez, J. Wenger, R. Thadhani, and D.J. Goldsmith Active vitamin d treatment for reduction of residual proteinuria: a systematic review J. Am. Soc. Nephrol. 24 2013 1863 1871
20. C.A. Keyzer, M.A. de Jong, G. Fenna van Breda, M.G. Vervloet, G.D. Laverman, M. Hemmelder, and et al. Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol Nephrol. Dial. Transplant. 2015 Epub ahead of print (pii: gfv033)
21. R. Beaglehole, R. Bonita, R. Horton, C. Adams, G. Alleyne, P. Asaria, and et al. Priority actions for the non-communicable disease crisis Lancet 377 2011 1438 1447
22. J. Powles, S. Fahimi, R. Micha, S. Khatibzadeh, P. Shi, M. Ezzati, and et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide BMJ Open 3 2013 e003733 10.1136/bmjopen-2013-003733
23. E.J. McMahon, J.D. Bauer, C.M. Hawley, N.M. Isbel, M. Stowasser, D.W. Johnson, and et al. A randomized trial of dietary sodium restriction in CKD J. Am. Soc. Nephrol. 24 2013 2096 2103
24. L. Vogt, F. Waanders, F. Boomsma, D. de Zeeuw, and G. Navis Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan J. Am. Soc. Nephrol. 19 2008 999 1007
25. N.R. Cook, J.A. Cutler, E. Obarzanek, J.E. Buring, K.M. Rexrode, S.K. Kumanyika, and et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP) BMJ 334 2007 885 888
26. J.A. Krikken, A.T. Lely, S.J. Bakker, and G. Navis The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men Kidney Int. 71 2007 260 265
27. H. Kobori, A. Nishiyama, Y. Abe, and L.G. Navar Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet Hypertension 41 2003 592 597
28. M.J. Kocks, H. Buikema, S. Gschwend, F. Boomsma, D. de Zeeuw, and G. Navis High dietary sodium blunts affects of angiotensin-converting enzyme inhibition on vascular angiotensin I-to-angiotensin II conversion in rats J. Cardiovasc. Pharmacol. 42 2003 601 606
29. G. Chandramohan, Y. Bai, K. Norris, B. Rodriguez-Iturbe, and N.D. Vaziri Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-kappaB activity in salt-sensitive and -resistant rat kidneys Am. J. Nephrol. 28 2008 158 167
30. W. Cao, A. Li, L. Wang, Z. Zhou, Z. Su, W. Bin, and et al. A salt-induced reno-cerebral reflex activates renin-angiotensin systems and promotes CKD progression J. Am. Soc. Nephrol. 26 2015 1619 1633
31. M.C. Slagman, T.Q. Nguyen, F. Waanders, L. Vogt, M.H. Hemmelder, G.D. Laverman, and et al. Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy Clin. J. Am. Soc. Nephrol. 6 2011 1845 1850
32. A.J. Kwakernaak, F. Waanders, M.C. Slagman, M.M. Dokter, G.D. Laverman, R.A. de Boer, and et al. Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients J. Hypertens 31 2013 2425 2432
33. M. Kleinewietfeld, A. Manzel, J. Titze, H. Kvakan, N. Yosef, R.A. Linker, and et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells Nature 496 2013 518 522
34. C. Wu, N. Yosef, T. Thalhamer, C. Zhu, S. Xiao, Y. Kishi, and et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1 Nature 496 2013 513 517
35. T. Korn, E. Bettelli, M. Oukka, and V.K. Kuchroo IL-17 and Th17 Cells Annu. Rev. Immunol. 27 2009 485 517
36. J.E. Turner, H.J. Paust, O.M. Steinmetz, and U. Panzer The Th17 immune response in renal inflammation Kidney Int. 77 2010 1070 1075
37. H.J. Paust, J.E. Turner, O.M. Steinmetz, A. Peters, F. Heymann, C. Holscher, and et al. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis J. Am. Soc. Nephrol. 20 2009 969 979
38. S.A. Summers, O.M. Steinmetz, M. Li, J.Y. Kausman, T. Semple, K.L. Edgtton, and et al. Th1 and Th17 cells induce proliferative glomerulonephritis J. Am. Soc. Nephrol. 20 2009 2518 2524
39. A. Chaudhry, D. Rudra, P. Treuting, R.M. Samstein, Y. Liang, A. Kas, and et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner Science 326 2009 986 991
40. M.A. Kluger, M. Luig, C. Wegscheid, B. Goerke, H.J. Paust, S.R. Brix, and et al. Stat3 programs Th17-specific regulatory T cells to control GN J. Am. Soc. Nephrol. 25 2014 1291 1302
41. G.R. MENEELY, and C.O. BALL Experimental epidemiology of chronic sodium chloride toxicity and the protective effect of potassium chloride Am. J. Med. 25 1958 713 725
42. M. O'Donnell, A. Mente, S. Rangarajan, M.J. McQueen, X. Wang, L. Liu, and et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events N. Engl. J. Med. 371 2014 612 623
43. A. Mente, M.J. O'Donnell, S. Rangarajan, M.J. McQueen, P. Poirier, A. Wielgosz, and et al. Association of urinary sodium and potassium excretion with blood pressure N. Engl. J. Med. 371 2014 601 611
44. A. Smyth, D. Dunkler, P. Gao, K.K. Teo, S. Yusuf, M.J. O'Donnell, and et al. The relationship between estimated sodium and potassium excretion and subsequent renal outcomes Kidney Int. 86 2014 1205 1212
45. S. Araki, M. Haneda, D. Koya, K. Kondo, S. Tanaka, H. Arima, and et al. Urinary potassium excretion and renal and cardiovascular complications in patients with type 2 diabetes and normal renal function Clin. J. Am. Soc. Nephrol. 10 2015 2152 2158
46. H.J. Adrogue, and N.E. Madias Sodium and potassium in the pathogenesis of hypertension N. Engl. J. Med. 356 2007 1966 1978
47. M.C. Slagman, F. Waanders, M.H. Hemmelder, A.J. Woittiez, W.M. Janssen, H.J. Lambers Heerspink, and et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial BMJ 343 2011 d4366
48. E.I. Ekinci, G. Thomas, D. Thomas, C. Johnson, R.J. Macisaac, C.A. Houlihan, and et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake Diabetes Care 32 2009 1398 1403
49. A.J. Kwakernaak, J.A. Krikken, S.H. Binnenmars, F.W. Visser, M.H. Hemmelder, A.J. Woittiez, and et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial Lancet Diabetes Endocrinol. 2 2014 385 395
50. J.E. Heeg, P.E. de Jong, G.K. van der Hem, and D. de Zeeuw Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril Kidney Int. 36 1989 272 279
51. M.R. Weir, A.M. Yadao, D. Purkayastha, and A.N. Charney Effects of high- and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren J. Cardiovasc. Pharmacol. Ther. 15 2010 356 363
52. G.D. Laverman, H. Van Goor, R.H. Henning, P.E. De Jong, D. De Zeeuw, and G. Navis Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes Kidney Int. 63 2003 64 71
53. K. Mirkovic, A.R. Frenay, J. van den Born, H. van Goor, G. Navis, and M.H. De Borst Sodium restriction potentiates the renoprotective effects of combined vitamin D receptor activation and angiotensin-converting enzyme inhibition in established proteinuric nephropathy Nephrol. Dial Transplant. 2015 Epub ahead of print (pii: gfv304)
54. E.I. Ekinci, S. Clarke, M.C. Thomas, J.L. Moran, K. Cheong, R.J. MacIsaac, and et al. Dietary salt intake and mortality in patients with type 2 diabetes Diabetes Care 34 2011 703 709
55. H.J. Lambers Heerspink, A. Kwakernaak, D. de Zeeuw, G. Navis, Comment on: Ekinci, and et al. Dietary salt intake and mortality in patients with type 2 diabetes Diabetes Care 34 2011 703 709 (Dabetes Care, 2011, 34, e124; author reply e125-0711)
56. Dabetes Care, 2011, 34, e124; author reply e125-0711
57. S. Vegter, A. Perna, M.J. Postma, G. Navis, G. Remuzzi, and P. Ruggenenti Sodium intake, ACE inhibition, and progression to ESRD J. Am. Soc. Nephrol. 23 2012 165 173
58. H.J. Heerspink, F.A. Holtkamp, H.H. Parving, G.J. Navis, J.B. Lewis, E. Ritz, and et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers Kidney Int. 82 2012 330 337
59. F.H. Wapstra, H. Van Goor, G. Navis, P.E. De Jong, and D. De Zeeuw Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis Clin. Sci. (Lond.) 90 1996 393 401
60. M. Boddi, L. Poggesi, M. Coppo, N. Zarone, S. Sacchi, C. Tania, and et al. Human vascular renin-angiotensin system and its functional changes in relation to different sodium intakes Hypertension 31 1998 836 842
61. F.G. van der Kleij, A. Schmidt, G.J. Navis, M. Haas, N. Yilmaz, P.E. de Jong, and et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status Kidney Int. Suppl. 63 1997 S23 6
62. G. Remuzzi, C. Zoja, E. Gagliardini, D. Corna, M. Abbate, and A. Benigni Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals J. Am. Soc. Nephrol. 10 1999 1542 1549
63. M. Abbate, C. Zoja, D. Rottoli, D. Corna, N. Perico, T. Bertani, and et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease J. Am. Soc. Nephrol. 10 1999 804 813
64. P. Hamar, J. Peti-Peterdi, Z. Razga, G. Kovacs, U. Heemann, and L. Rosivall Coinhibition of immune and renin-angiotensin systems reduces the pace of glomerulosclerosis in the rat remnant kidney J. Am. Soc. Nephrol. 10 Suppl. 11 1999 S234 8
65. D.C. Cattran, G.B. Appel, L.A. Hebert, L.G. Hunsicker, M.A. Pohl, W.E. Hoy, and et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial Kidney Int. 59 2001 1484 1490
66. M. Praga, V. Barrio, G.F. Juarez, and J. Luno Grupo Espanol de Estudio de la Nefropatia Membranosa Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial Kidney Int. 71 2007 924 930
67. N. Duncan, A. Dhaygude, J. Owen, T.D. Cairns, M. Griffith, A.G. McLean, and et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy Nephrol. Dial Transplant. 19 2004 3062 3067
68. A.B. Kramer, G.D. Laverman, H. van Goor, and G. Navis Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage J. Pathol. 201 2003 160 167
69. A.B. Kramer, H. Bos, H. van Goor, and G.J. Navis Sodium intake modifies the negative prognostic value of renal damage prior to treatment with ACE inhibitors on proteinuria induced by adriamycin Nephron Physiol. 103 2006 43 52
70. W.E. Mitch Beneficial responses to modified diets in treating patients with chronic kidney disease Kidney Int. Suppl. 94 2005 S133 S135
71. A. Smyth, D. Dunkler, P. Gao, K.K. Teo, S. Yusuf, M.J. O'Donnell, and et al. The relationship between estimated sodium and potassium excretion and subsequent renal outcomes Kidney Int. 86 2014 1205 1212
72. M.M. Joosten, R.T. Gansevoort, K.J. Mukamal, P. van der Harst, J.M. Geleijnse, E.J. Feskens, and et al. Urinary and plasma magnesium and risk of ischemic heart disease Am. J. Clin. Nutr. 97 2013 1299 1306
73. S.J. Sinkeler, A.J. Kwakernaak, S.J. Bakker, S. Shahinfar, E. Esmatjes, D. de Zeeuw, and et al. Creatinine excretion rate and mortality in type 2 diabetes and nephropathy Diabetes Care 36 2013 1489 1494
74. K. Bibbins-Domingo, G.M. Chertow, P.G. Coxson, A. Moran, J.M. Lightwood, M.J. Pletcher, and et al. Projected effect of dietary salt reductions on future cardiovascular disease N. Engl. J. Med. 362 2010 590 599
75. M.H. de Borst, and G. Navis Dietary salt reductions and cardiovascular disease N. Engl. J. Med. 362 2010 2224 2225 Author reply 2225-6
76. Y. Meuleman, L. Ten Brinke, A.J. Kwakernaak, L. Vogt, J.I. Rotmans, W.J. Bos, and et al. Perceived barriers and support strategies for reducing sodium intake in patients with chronic kidney disease: a qualitative study Int. J. Behav. Med. 22 2015 530 539
77. N. Goraya, J. Simoni, C. Jo, and D.E. Wesson Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy Kidney Int. 81 2012 86 93
78. C. Zoccali, P. Ruggenenti, A. Perna, D. Leonardis, R. Tripepi, G. Tripepi, and et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition J. Am. Soc. Nephrol. 22 2011 1923 1930
79. J.K. Humalda, H.J. Lambers Heerspink, A.J. Kwakernaak, M.C. Slagman, F. Waanders, M.G. Vervloet, and et al. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade Am. J. Kidney Dis. 65 2015 259 266
80. M.H. de Borst, M.G. Vervloet, P.M. ter Wee, and G. Navis Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease J. Am. Soc. Nephrol. 22 2011 1603 1609
81. J.K. Humalda, C.A. Keyzer, S.H. Binnenmars, A.J. Kwakernaak, M.C. Slagman, G.D. Laverman, S.J. Bakker, M.H. De Borst, and G. Navis Concordance of dietary sodium intake and concomitant phosphate load: implications for sodium interventions Nutr. Metab. Cardiovasc. Dis. 2016 (Provisionally accepted)